Project Grant R43FD007525
Award Date 9/20/22
Completion Date 5/31/24
Dollars Obligated $519K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Portland, OR 97212, USA
Similar Awards
- This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), aims to improve mucosal melanoma therapy by harnessing the immunogenicity of the R3LCMV virus. The $667,553 award to Northwestern University, spanning 2025-2029, has two key objectives: Determine whether neoadjuvant R3LCMV treatment improves disease-free survival in dogs with naturally occurring mucosal melanoma through a placebo-controlled veterinary...
- This $131,910 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to Virginia Polytechnic Institute & State University (Virginia Tech) seeks to further the development of histotripsy, a non-thermal ablation technique, for the treatment of osteosarcoma (OS) in dogs. The project aims to: 1) investigate the treatment parameters and strategies needed for complete ablation of ex vivo canine OS tumors, and 2) test these strategies in pilot clinical...
- This $672,844 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research conducted by Northwestern University to target the MHC I chain-related molecule (MIC) to augment adoptive natural killer (NK) cell therapy using the canine soft tissue sarcoma model. The research aims to better understand and optimize combination therapy approaches involving anti-MIC antibodies that can modulate the tumor microenvironment to reinvigorate CD8...
- Oregon State University will receive $500,000 from the National Science Foundation under the Technology, Innovation, and Partnerships program to develop cancer therapeutics for dogs. Specifically, the university will construct and test prototype dual epitope-binding therapeutic antibodies targeting the canine PD-1 protein for the treatment of canine cancers. Researchers will design various single domain antibody configurations and select an optimal construct using recombinant DNA methods and...
- This $125,685 Project Grant award from the National Institutes of Health's (NIH) Office of Research Infrastructure Programs (CFDA 93.351) will support a comparative analysis of DNA damage and repair capacity in dogs to improve cancer risk prediction. The Broad Institute, Inc. will conduct this research to better understand the higher incidence of cancer and faster accumulation of somatic mutations in dogs compared to humans. The study will assess contributions from increased exposure to...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $400,000 to Senex Biotechnology Inc. to develop a nanoparticle formulation of a mediator kinase inhibitor drug candidate, SNX631-6, for the treatment of peritoneal ovarian cancer metastases. The goal is to optimize the nanoparticle formulation for improved pharmacokinetics and efficacy compared to oral administration when delivered intraperitoneally. The project will assess the...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $210,789 to Texas A&M University System Health Science Center to conduct research on a DKK-1 targeting antisense therapy for osteosarcoma. The research aims to characterize the effects of a canine version of the DKK-1 inhibiting antisense therapy (cDKKMO) on canine osteosarcoma cell lines and patient-derived xenografts, as well as test the therapy's ability to inhibit tumor...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $419,080.00 to Virginia Polytechnic Institute & State University (Virginia Tech) to evaluate a combination therapy approach using histotripsy tumor ablation and the immunostimulant n-dihydrogalactochitosan (GC) for treating osteosarcoma. The award will fund a comparative oncology study that incorporates murine preclinical models and pet dogs with spontaneous appendicular...
- The National Cancer Institute (NCI) awarded Lifengine Animal Health Laboratories Incorporated a $400,000 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395). The award period runs from August 4, 2025 to July 31, 2026. The grant funds the development of chimeric antigen receptor (CAR)-T cell therapies that can overcome functional exhaustion by overexpressing the C-MYB transcription factor. This research aims to improve the therapeutic efficacy and duration of...
- The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394), awarded a $399,444 Project Grant to Cancure LLC (Canzx Biotherapeutics) on August 1, 2025. The funding will support a feasibility study of a novel agent that aims to stimulate NK (natural killer) and CD8 T cells for potential use in treating solid tumors. The study seeks to address challenges with persistence and sustained function of these cell-based therapies in the solid...